

Jun Luo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3072563/publications.pdf>

Version: 2024-02-01

105
papers

10,791
citations

66343

42
h-index

39675

94
g-index

110
all docs

110
docs citations

110
times ranked

10423
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 97-101.	1.9	14
2	Germline <i>BRCA2</i> , <i>ATM</i> and <i>CHEK2</i> alterations shape somatic mutation landscapes in prostate cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 148-148.	1.6	0
3	A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. <i>European Urology</i> , 2021, 79, 692-699.	1.9	49
4	Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer. <i>Translational Oncology</i> , 2021, 14, 100915.	3.7	27
5	A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 220-232.	3.9	3
6	Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase 2 nonrandomized clinical trial. <i>Prostate</i> , 2021, 81, 326-338.	2.3	35
7	Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 157-157.	1.6	0
8	Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. <i>European Journal of Cancer</i> , 2021, 144, 302-309.	2.8	29
9	Effect of COVID-19 on childhood <i>Mycoplasma pneumoniae</i> infection in Chengdu, China. <i>BMC Pediatrics</i> , 2021, 21, 202.	1.7	24
10	Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. <i>JCI Insight</i> , 2021, 6, .	5.0	22
11	Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. <i>Clinical Cancer Research</i> , 2021, 27, 4077-4088.	7.0	21
12	AR Splicing Variants and Resistance to AR Targeting Agents. <i>Cancers</i> , 2021, 13, 2563.	3.7	27
13	Clonal hematopoiesis in prostate cancer inferred from somatic tumor profiling. <i>Journal of Clinical Oncology</i> , 2021, 39, e17001-e17001.	1.6	2
14	Specific Detection of Prostate Cancer Cells in Urine by RNA In Situ Hybridization. <i>Journal of Urology</i> , 2021, 206, 37-43.	0.4	4
15	Reciprocal <i>YAP1</i> loss and <i>INSM1</i> expression in neuroendocrine prostate cancer. <i>Journal of Pathology</i> , 2021, 255, 425-437.	4.5	12
16	Delineating the Molecular Events Underlying Development of Prostate Cancer Variants with Neuroendocrine/Small Cell Carcinoma Characteristics. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12742.	4.1	4
17	Mitochondrial-Associated Protein LRPPRC is Related With Poor Prognosis Potentially and Exerts as an Oncogene Via Maintaining Mitochondrial Function in Pancreatic Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 817672.	2.3	10
18	Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 225-239.	2.8	18

#	ARTICLE	IF	CITATIONS
19	CDK12 Mutation in Advanced Prostate Cancer: A Marker for Clinical Subtype?. <i>European Urology</i> , 2020, 77, 342-343.	1.9	3
20	A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. <i>Nature Cancer</i> , 2020, 1, 1082-1096.	13.2	49
21	Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. <i>Oncogene</i> , 2020, 39, 6935-6949.	5.9	60
22	Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1285-1301.	3.0	42
23	Predictive Biomarkers in Prostate Cancer: Is It Time To Go "All In" on Liquid Biopsies?. <i>European Urology</i> , 2020, 78, 181-183.	1.9	3
24	The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer. <i>Nature Communications</i> , 2020, 11, 2689.	12.8	41
25	Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 381-397.	3.9	34
26	Androgen receptor variant-driven prostate cancer II: advances in clinical investigation. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 367-380.	3.9	22
27	Regulation of androgen receptor variants in prostate cancer. <i>Asian Journal of Urology</i> , 2020, 7, 251-257.	1.2	19
28	SF3B2-Mediated RNA Splicing Drives Human Prostate Cancer Progression. <i>Cancer Research</i> , 2019, 79, 5204-5217.	0.9	51
29	Reply to L. Dirix, B. De Laere et al, and A. Sharp et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 2184-2186.	1.6	7
30	A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. <i>Prostate</i> , 2019, 79, 1597-1603.	2.3	18
31	Androgen Receptor Modulation Optimized for Response" Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7" expressing Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 843-851.	1.9	36
32	Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 676-685.	1.9	62
33	Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1120-1129.	1.6	267
34	Detection of androgen receptor (AR) and AR-V7 in small cell prostate carcinoma: Diagnostic and therapeutic implications. <i>Asian Journal of Urology</i> , 2019, 6, 109-113.	1.2	7
35	Approaches to urinary detection of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 362-381.	3.9	52
36	PARP inhibition " not all gene mutations are created equal. <i>Nature Reviews Urology</i> , 2019, 16, 4-6.	3.8	17

#	ARTICLE	IF	CITATIONS
37	Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy-naïve salivary duct carcinomas. <i>Human Pathology</i> , 2019, 84, 173-182.	2.0	15
38	Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage. <i>Journal of Clinical Investigation</i> , 2019, 129, 4245-4260.	8.2	67
39	Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. <i>European Urology</i> , 2018, 74, 218-225.	1.9	140
40	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. <i>European Urology</i> , 2018, 73, 715-723.	1.9	105
41	Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. <i>Journal of Urology</i> , 2018, 199, 1494-1501.	0.4	21
42	Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. <i>American Journal of Pathology</i> , 2018, 188, 1478-1485.	3.8	119
43	Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. <i>Lancet Oncology</i> , The, 2018, 19, 76-86.	10.7	149
44	Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. <i>Journal of Clinical Investigation</i> , 2018, 129, 192-208.	8.2	266
45	Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. <i>Oncotarget</i> , 2018, 9, 28561-28571.	1.8	129
46	Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 6810-6815.	7.1	120
47	Detection of AR-V7 transcript with RNA in situ hybridization in human salivary duct cancer. <i>Oral Oncology</i> , 2018, 84, 134-136.	1.5	4
48	Germline mutations in <i>PPFIBP2</i> are associated with lethal prostate cancer. <i>Prostate</i> , 2018, 78, 1222-1228.	2.3	12
49	Alternative splicing in prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 663-675.	27.6	142
50	Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. <i>European Urology Oncology</i> , 2018, 1, 151-159.	5.4	28
51	Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2018, 73, 727-735.	1.9	55
52	Effect of germline DNA repair gene mutations on outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide. <i>Journal of Clinical Oncology</i> , 2018, 36, 221-221.	1.6	0
53	Clinical utility of androgen-receptor splice variant 7 (AR-V7) determinations in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). <i>Journal of Clinical Oncology</i> , 2018, 36, e17067-e17067.	1.6	0
54	Prevalence of residual tumor in the prostate after contemporary systemic therapy. <i>Journal of Clinical Oncology</i> , 2018, 36, e17001-e17001.	1.6	0

#	ARTICLE	IF	CITATIONS
55	The prognostic and predictive value of AR-V7 quantification in mCRPC.. Journal of Clinical Oncology, 2018, 36, 12026-12026.	1.6	0
56	Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 Å® to Suppress Enzalutamide-resistant Prostate Cancer Progression. European Urology, 2017, 72, 835-844.	1.9	103
57	Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting. Journal of Molecular Diagnostics, 2017, 19, 115-125.	2.8	41
58	Reply to Julie Steinestel, Christof Bernemann, Andres J. Schrader, and Jochen K. Lennerz's Letter to the Editor re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. J Clin Oncol 2017;35:2149-2156. AR-V7 Testing: What's in it for the Patient?. European Urology, 2017, 72, e170-e171.	1.9	1
59	Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. Journal of Clinical Oncology, 2017, 35, 2149-2156.	1.6	371
60	Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2017, 2017, 1-9.	3.0	42
61	Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 5005-5005.	1.6	23
62	Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 5035-5035.	1.6	19
63	Clinical utility of CLIA-grade AR-V7 testing in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 183-183.	1.6	1
64	Analytic Validation of RNA <i>In Situ</i> Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer. Clinical Cancer Research, 2016, 22, 4651-4663.	7.0	34
65	Blood Based Detection of Androgen Receptor Splice Variants in Patients with Advanced Prostate Cancer. Journal of Urology, 2016, 196, 1606-1607.	0.4	5
66	Non-invasive actionable biomarkers for metastatic prostate cancer. Asian Journal of Urology, 2016, 3, 170-176.	1.2	8
67	Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer. Oncologist, 2016, 21, 1427-1435.	3.7	60
68	Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. Prostate, 2016, 76, 1484-1490.	2.3	29
69	An Immune-Inflammation Gene Expression Signature in Prostate Tumors of Smokers. Cancer Research, 2016, 76, 1055-1065.	0.9	31
70	AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): Expanded analysis of the Johns Hopkins cohort.. Journal of Clinical Oncology, 2016, 34, 5012-5012.	1.6	16
71	Targeted suppression of AR-V7 using PIP5K1Î± inhibitor overcomes enzalutamide resistance in prostate cancer cells. Oncotarget, 2016, 7, 63065-63081.	1.8	38
72	Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening. Oncotarget, 2016, 7, 72593-72607.	1.8	71

#	ARTICLE	IF	CITATIONS
73	Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2016, 18, 580.	1.6	38
74	Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2015, 1, 582.	7.1	552
75	AR splice variant dimerization—clinical implications. <i>Nature Reviews Urology</i> , 2015, 12, 431-433.	3.8	10
76	A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells. <i>Cancer Immunology Research</i> , 2015, 3, 1175-1184.	3.4	38
77	Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study. <i>Science Translational Medicine</i> , 2015, 7, 269ra2.	12.4	205
78	Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. <i>Clinical Cancer Research</i> , 2015, 21, 5619-5629.	7.0	56
79	Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone. <i>Hormones and Cancer</i> , 2014, 5, 265-273.	4.9	102
80	AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1028-1038.	27.0	2,233
81	DNA Methylation Alterations Exhibit Intra-individual Stability and Inter-individual Heterogeneity in Prostate Cancer Metastases. <i>Science Translational Medicine</i> , 2013, 5, 169ra10.	12.4	231
82	The Expression Signature of Androgen Receptor Splice Variants and Their Distinctive Transcriptional Activities in Castration-Resistant Prostate Cancer. , 2013, , 201-213.		2
83	Decoding the androgen receptor splice variants. <i>Translational Andrology and Urology</i> , 2013, 2, 178-186.	1.4	115
84	Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2012, 72, 3457-3462.	0.9	518
85	Molecular profiling of indolent human prostate cancer: tackling technical challenges to achieve high-fidelity genome-wide data. <i>Asian Journal of Andrology</i> , 2012, 14, 385-392.	1.6	4
86	A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. <i>Prostate</i> , 2011, 71, 1656-1667.	2.3	177
87	Definition of a FoxA1 Cistrome That Is Crucial for G1 to S-Phase Cell-Cycle Transit in Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2011, 71, 6738-6748.	0.9	87
88	A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. , 2011, 71, 1656.		1
89	Expression of cancer/testis antigens in prostate cancer is associated with disease progression. <i>Prostate</i> , 2010, 70, 1778-1787.	2.3	60
90	Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. <i>Expert Review of Endocrinology and Metabolism</i> , 2010, 5, 753-764.	2.4	44

#	ARTICLE	IF	CITATIONS
91	Use of Expression Microarrays in Cancer Research. , 2010, , 67-85.		0
92	Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer. Cancer Research, 2009, 69, 16-22.	0.9	939
93	Genome-wide expression analysis of recently processed formalin-fixed paraffin embedded human prostate tissues. Prostate, 2009, 69, 214-218.	2.3	17
94	Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nature Medicine, 2009, 15, 559-565.	30.7	596
95	Explaining hormone-deprivation therapy failure in prostate cancer patients. Expert Review of Endocrinology and Metabolism, 2009, 4, 103-105.	2.4	0
96	GOLPH2 and MYO6: Putative prostate cancer markers localized to the Golgi apparatus. Prostate, 2008, 68, 1387-1395.	2.3	69
97	Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Modern Pathology, 2008, 21, 1156-1167.	5.5	363
98	Marrow Stromal Cells as Universal Donor Cells for Cardiac Regenerative Therapy: Fact or Fancy?. , 2008, , 117-137.		1
99	A Novel Role of Myosin VI in Human Prostate Cancer. American Journal of Pathology, 2006, 169, 1843-1854.	3.8	133
100	Trefoil factor 3 overexpression in prostatic carcinoma: Prognostic importance using tissue microarrays. Prostate, 2004, 61, 215-227.	2.3	85
101	PROSTATE CANCER DETECTION ON URINALYSIS FOR \pm METHYLACYL COENZYME A RACEMASE PROTEIN. Journal of Urology, 2004, 172, 1501-1503.	0.4	97
102	Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinoma. Prostate, 2003, 57, 134-139.	2.3	111
103	Looking Beyond Morphology: Cancer Gene Expression Profiling Using DNA Microarrays. Cancer Investigation, 2003, 21, 937-949.	1.3	45
104	Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate, 2002, 51, 189-200.	2.3	119
105	Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Research, 2002, 62, 2220-6.	0.9	384